Selection of Phase I Service Providers
Applied Clinical Trials
Tufts CSDD
What are the most important factors in selecting a Phase I service provider?
That depends how we look at the data from ISR's latest report, "2012 CRO Quality Benchmarking—Phase I Service Providers." Of the 61 executives responsible for Phase I study conduct and outsourcing, more selected "prior positive experience with a service provider" than any other attribute as the single most important driver of selection. However, when asked to indicate their top five drivers of selection, more respondents chose "access to patient populations" among their top five than any other attribute.
Attributes that fuel service provider selection.
This is notable considering the other 20 attributes respondents had to choose from are historically critical skills such as therapeutic expertise, project management, timelines management, and even the experience of the Phase I unit's lead investigator.
For now, historical relationships will continue to get a Phase I provider invited to bid.
Going forward, the ability to demonstrate patient—not just healthy volunteer—recruitment capabilities will make the difference between a win and a loss.
—Industry Standard Research, www.ISRreports.com.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
